TD Cowen analyst Charles Rhyee maintained a Buy rating on GoodRx Holdings yesterday and set a price target of $7.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Charles Rhyee has given his Buy rating due to a combination of factors including the company’s revised financial projections and strategic growth initiatives. Despite GoodRx Holdings missing its second-quarter estimates and adjusting its 2025 revenue and EBITDA guidance, Rhyee sees potential in the company’s future performance. The updated estimates for 2025 and 2026 suggest a steady increase in both adjusted EBITDA and revenue, indicating a positive outlook for the company’s financial health.
Furthermore, management’s commentary on raising the revenue growth target for their Man Sol segment to approximately 30% reflects a strong strategic direction. Although the price target was adjusted from $8 to $7, Rhyee believes that the stock still holds value, with shares expected to trade at around 10 times the enterprise value by 2026. This outlook supports the Buy rating, as the company’s strategic initiatives and financial adjustments are anticipated to drive long-term growth.
In another report released on August 7, Citi also maintained a Buy rating on the stock with a $5.75 price target.